A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Public ClinicalTrials.gov record NCT00794417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT00794417
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008 (Actual)
- Primary completion
- Jun 30, 2011 (Actual)
- Completion
- Jun 30, 2011 (Actual)
- Last update posted
- Dec 10, 2020
2008 – 2011
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Institute, LLC | Tucson | Arizona | 85715 | — |
| University of Arkansas for Medical Science | Little Rock | Arkansas | 72205 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| Palm Beach Institute of Hematology and Oncology | Boynton Beach | Florida | 33435 | — |
| Edward Hines Jr. VA Medical Center | Hines | Illinois | 60141 | — |
| Kentucky Cancer Clinic | Hazard | Kentucky | 41701 | — |
| Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231-1000 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| UNM Cancer Clinic | Albuquerque | New Mexico | 87131 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Presbyterian Hospital Center for Cancer Research | Charlotte | North Carolina | 28204 | — |
| Erie Regional Cancer Center | Erie | Pennsylvania | 16505 | — |
| Schiffler Cancer Center - Medical Oncology Division | Wheeling | West Virginia | 26003 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00794417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2020 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00794417 live on ClinicalTrials.gov.